Extended-Release Pseudoephedrine Trial Results “Positive,” SCOLR Says
This article was originally published in The Tan Sheet
Executive Summary
The first of three human studies evaluating SCOLR Pharma's extended-release pseudoephedrine tablets has shown "positive" initial results, the company announced March 28
You may also be interested in...
SCOLR controlled-delivery drugs
SCOLR Pharma plans to develop 24-hour OTC pseudoephedrine decongestant and12-hour OTC combination ibuprofen/pseudoephedrine cough/cold products using the company's controlled delivery technology (CDT) platform, the firm says April 13. All three products are in the preclinical stages of development. The Bellevue, Wash.-based firm recently announced positive results from trials on 12-hour CDT pseudoephedrine and ibuprofen products and intends to submit both for FDA approval this summer (1"The Tan Sheet" April 4, 2005, p. 15)...
Ibuprofen Extended-Release NDA Slated For 2005, SCOLR Pharma Says
SCOLR Pharma plans to file an NDA in summer 2005 for CDT extended-release 12-hour ibuprofen tablets, the firm announced July 26
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC